Skip to content
2000
Volume 25, Issue 11
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Nitrogen-based organic heterocyclic compounds are an important source of therapeutic agents. About 75% of drugs approved by the FDA and currently available in the market are N-heterocyclic organic compounds. The N-heterocyclic organic compounds like pyridine, indole, triazoles, triazine, imidazoles, benzimidazoles, quinazolines, pyrazoles, quinolines, pyrimidines, porphyrin, . have demonstrated significant biological activities. These heterocyclic organic compounds also coordinate with various metal ions and form coordination compounds. Most of them have shown improved biological activities. The research on the metal complexes of these compounds reported their significant biological activities. N-heterocyclic-based metal complexes showed outstanding anticancer activities against different cancer cell lines, including VEGFR-2, HT-29, MDA-MB-231, MCF-7 K562, A549, HepG2, HL60, A2780, WI-38, Colo-205, PC-3, and other cancer cell lines. Some of these compounds showed better anticancer activity than cisplatin. In this review, we summarized the anticancer properties of N-heterocyclic-based gold (Au), silver (Ag), and copper (Cu) complexes and explored the mechanisms of action and potential structure-activity relationships (SAR) of these complexes. Our goal is to assist researchers in designing highly potent N-heterocyclic-based Au, Ag, and Cu complexes for the potential treatment of various cancers.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206331002241119145651
2025-01-03
2025-09-04
Loading full text...

Full text loading...

References

  1. Al-SaidiH.M. KhanS. A review on organic fluorimetric and colorimetric chemosensors for the detection of Ag(I) ions.Crit. Rev. Anal. Chem.20225211810.1080/10408347.2022.2133561 36251012
    [Google Scholar]
  2. KhanS. AlhumaydhiF.A. IbrahimM.M. AlqahtaniA. AlshamraniM. AlruwailiA.S. HassanianA.A. KhanS. Recent advances and therapeutic journey of schiff base complexes with selected metals (Pt, Pd, Ag, Au) as potent anticancer agents: A review.Anticancer. Agents Med. Chem.202222183086309610.2174/1871520622666220511125600 35546764
    [Google Scholar]
  3. KhanS. ChenX. AlmahriA. AllehyaniE.S. AlhumaydhiF.A. IbrahimM.M. AliS. Recent developments in fluorescent and colorimetric chemosensors based on schiff bases for metallic cations detection: A review.J. Environ. Chem. Eng.20219610638110.1016/j.jece.2021.106381
    [Google Scholar]
  4. KhanS. MuhammadM. Al-SaidiH.M. HassanianA.A. AlharbiW. AlharbiK.H. Synthesis, characterization and applications of schiff base chemosensor for determination of Cu2+ ions.J. Saudi Chem. Soc.202226410150310.1016/j.jscs.2022.101503
    [Google Scholar]
  5. Mohammad Abu-TaweelG. IbrahimM.M. KhanS. Al-SaidiH.M. AlshamraniM. AlhumaydhiF.A. AlharthiS.S. Medicinal importance and chemosensing applications of pyridine derivatives: A review.Crit. Rev. Anal. Chem.202254359961610.1080/10408347.2022.2089839 35724248
    [Google Scholar]
  6. KerruN. GummidiL. MaddilaS. GanguK.K. JonnalagaddaS.B. A review on recent advances in nitrogen-containing molecules and their biological applications.Molecules2020258190910.3390/molecules25081909
    [Google Scholar]
  7. AlrooqiM. KhanS. AlhumaydhiF.A. AsiriS.A. AlshamraniM. MashraqiM.M. AlzamamiA. AlshahraniA.M. AldahishA.A. A therapeutic journey of pyridine-based heterocyclic compounds as potent anticancer agents: A review (from 2017 to 2021).Anticancer. Agents Med. Chem.202222152775278710.2174/1871520622666220324102849 35331100
    [Google Scholar]
  8. ChiacchioM.A. IannazzoD. RomeoR. GiofrèS.V. LegnaniL. Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents.Curr. Med. Chem.202026407166719510.2174/0929867325666180904125400 30182842
    [Google Scholar]
  9. NuralY. OzdemirS. YalcinM.S. DemirB. AtabeyH. SeferogluZ. EceA. New bis- and tetrakis-1,2,3-triazole derivatives: Synthesis, DNA cleavage, molecular docking, antimicrobial, antioxidant activity and acid dissociation constants.Bioorg. Med. Chem. Lett.20225512845310.1016/j.bmcl.2021.128453 34801684
    [Google Scholar]
  10. XuH. LvM. Developments of indoles as anti-HIV-1 inhibitors.Curr. Pharm. Des.200915182120214810.2174/138161209788489168 19519449
    [Google Scholar]
  11. KüçükgüzelG. Çikla-SüzgünP. Recent advances bioactive 1,2,4-triazole-3-thiones.Eur. J. Med. Chem.2015830-870.97 10.1016/j.ejmech.2014.11.033
    [Google Scholar]
  12. GabaM. MohanC. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions.Med. Chem. Res.20152517321010.1007/s00044‑015‑1495‑5
    [Google Scholar]
  13. KadhimM.I. HuseinI. Pharmaceutical and biological application of new synthetic compounds of pyranone, pyridine, pyrmidine, pyrazole and isoxazole incorporating on 2-flouroquinoline moieties.Syst. Rev. Pharm.202011267968410.5530/SRP.2020.2.98
    [Google Scholar]
  14. FariaJ.V. VegiP.F. MiguitaA.G.C. dos SantosM.S. BoechatN. BernardinoA.M.R. Recently reported biological activities of pyrazole compounds.Bioorg. Med. Chem.201725215891590310.1016/j.bmc.2017.09.035
    [Google Scholar]
  15. OmarA. SalehN.M. Abdel-RahmanA.A-H. El-AdlK. Review article; Anticancer activities of some fused heterocyclic moieties containing nitrogen and/or sulfur heteroatoms. Al-Azhar.J. Pharm. Sci.2020622395410.21608/ajps.2020.118375
    [Google Scholar]
  16. MaD.L. WuC. WuK.J. LeungC.H. Iridium(III) complexes targeting apoptotic cell death in cancer cells.Molecules20192415273910.3390/molecules24152739
    [Google Scholar]
  17. KatsarosN. AnagnostopoulouA. Rhodium and its compounds as potential agents in cancer treatment.Crit. Rev. Oncol. Hematol.200242329730810.1016/S1040‑8428(01)00222‑0 12050021
    [Google Scholar]
  18. D’AmatoA. MaricondaA. IacopettaD. CeramellaJ. CatalanoA. SinicropiM.S. LongoP. Complexes of ruthenium(II) as promising dual-active agents against cancer and viral infections.Pharmaceuticals (Basel)20231612172910.3390/ph16121729
    [Google Scholar]
  19. ZhangC. XuC. GaoX. YaoQ. Platinum-based drugs for cancer therapy and anti-tumor strategies.Theranostics20221252115213210.7150/thno.69424 35265202
    [Google Scholar]
  20. MaD.L. WangM. MaoZ. YangC. NgC.T. LeungC.H. Rhodium complexes as therapeutic agents.Dalton Trans.20164572762277110.1039/C5DT04338G 26743935
    [Google Scholar]
  21. JinS. GuoY. GuoZ. WangX. Monofunctional platinum(II) anticancer agents.Pharmaceuticals (Basel)202114213310.3390/ph14020133
    [Google Scholar]
  22. TanS.J. YanY.K. LeeP.P.F. LimK.H. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.Future Med. Chem.20102101591160810.4155/fmc.10.234 21426151
    [Google Scholar]
  23. MediciS. PeanaM. NurchiV.M. LachowiczJ.I. CrisponiG. ZorodduM.A. Noble metals in medicine: Latest advances.Coord. Chem. Rev.201528432935010.1016/j.ccr.2014.08.002
    [Google Scholar]
  24. VechalapuS.K. KumarR. SachanS.K. ShaikhK. MahapatraA.D. DraksharapuA. AllimuthuD. Copper and manganese complexes of pyridinecarboxaldimine induce oxidative cell death in cancer cells.ACS Appl. Bio Mater.20247106696670510.1021/acsabm.4c00854 39240687
    [Google Scholar]
  25. KalaraniR. SankarganeshM. KumarG.G.V. KalanithiM. Synthesis, spectral, DFT calculation, sensor, antimicrobial and DNA binding studies of Co(II), Cu(II) and Zn(II) metal complexes with 2-amino benzimidazole Schiff base.J. Mol. Struct.2020120612772510.1016/j.molstruc.2020.127725
    [Google Scholar]
  26. SankarganeshM. VSolomon R. D RajaJ. Platinum complex with pyrimidine- and morpholine-based ligand: Synthesis, spectroscopic, DFT, TDDFT, catalytic reduction, in vitro anticancer, antioxidant, antimicrobial, dna binding and molecular modeling studies.J. Biomol. Struct. Dyn.20213931055106710.1080/07391102.2020.1727364 32036758
    [Google Scholar]
  27. YellolJ. PérezS.A. BucetaA. YellolG. DonaireA. SzumlasP. BednarskiP.J. MakhloufiG. JaniakC. EspinosaA. RuizJ. NovelC. NovelC. N-Cyclometalated benzimidazole ruthenium(II) and iridium(III) complexes as antitumor and antiangiogenic agents: A structure-activity relationship study.J. Med. Chem.201558187310732710.1021/acs.jmedchem.5b01194 26313136
    [Google Scholar]
  28. El-BoraeyH.A. EmamS.M. TolanD.A. El-NahasA.M. Structural studies and anticancer activity of a novel (N6O4) macrocyclic ligand and its Cu(II) complexes.Spectrochim. Acta A Mol. Biomol. Spectrosc.201178136037010.1016/j.saa.2010.10.021 21081283
    [Google Scholar]
  29. ShenK. HanX. LiC. HuangG. MaoS. ShiX. WuH. Synthesis, structure, electrochemical properties, and antioxidant activities of copper(II) and zinc(II) complexes with N,N-bis(N-ethyl-2-ylmethylbenzimidazol)allylamine ligand.J. Coord. Chem.201871798099010.1080/00958972.2018.1454593
    [Google Scholar]
  30. KesavanM.P. V KumarG.G. D RJ. AnithaK. KarthikeyanS. RajeshJ. DNA interaction, antimicrobial, antioxidant and anticancer studies on Cu(II) complexes of Luotonin A.J. Photochem. Photobiol. B2017167202810.1016/j.jphotobiol.2016.11.024 28039786
    [Google Scholar]
  31. KanthechaD.A. BhattB.S. PatelM.N. Synthesis, characterization and biological activities of imidazo[1,2-a]pyridine based gold(III) metal complexes.Heliyon201956e0196810.1016/j.heliyon.2019.e01968 31294115
    [Google Scholar]
  32. RubbianiR. ZehnderT.N. MariC. BlacqueO. VenkatesanK. GasserG. Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes.ChemMedChem20149122781279010.1002/cmdc.201402446 25377650
    [Google Scholar]
  33. TrommenschlagerA. ChotardF. BertrandB. AmorS. DondaineL. PicquetM. RichardP. BettaïebA. Le GendreP. PaulC. GozeC. BodioE. Gold(i)–BODIPY–imidazole bimetallic complexes as new potential anti-inflammatory and anticancer trackable agents.Dalton Trans.201746258051805610.1039/C7DT01377A 28594007
    [Google Scholar]
  34. SerraticeM. BertrandB. JanssenE.F.J. HemeltE. ZuccaA. CoccoF. CinelluM.A. CasiniA. Gold(i) compounds with lansoprazole-type ligands: Synthesis, characterization and anticancer properties in vitro.MedChemComm2014591418142210.1039/C4MD00241E
    [Google Scholar]
  35. TurekJ. RůžičkováZ. TloušťováE. Mertlíková-KaiserováH. GünterováJ. RulíšekL. RůžičkaA. 1,2,4‐Triazole‐based N ‐heterocyclic carbene complexes of gold(I): Synthesis, characterization and biological activity.Appl. Organomet. Chem.201630531832210.1002/aoc.3434
    [Google Scholar]
  36. SankarganeshM. D RajaJ. SakthikumarK. SolomonR.V. RajeshJ. AthimoolamS. VijayakumarV. New bio-sensitive and biologically active single crystal of pyrimidine scaffold ligand and its gold and platinum complexes: DFT, antimicrobial, antioxidant, DNA interaction, molecular docking with DNA/BSA and anticancer studies.Bioorg. Chem.20188114415610.1016/j.bioorg.2018.08.006 30121002
    [Google Scholar]
  37. SankarganeshM. RajaJ.D. RevathiN. SolomonR.V. KumarR.S. Gold(III) complex from pyrimidine and morpholine analogue Schiff base ligand: Synthesis, characterization, DFT, TDDFT, catalytic, anticancer, molecular modeling with DNA and BSA and DNA binding studies.J. Mol. Liq.201929411165510.1016/j.molliq.2019.111655
    [Google Scholar]
  38. SunR.W.Y. LokC.N. FongT.T.H. LiC.K.L. YangZ.F. ZouT. SiuA.F-M. CheC-M. A dinuclear cyclometalated gold(iii)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo.Chem. Sci. (Camb.)2013451979198810.1039/c3sc21972k
    [Google Scholar]
  39. CuinA. MassabniA.C. PereiraG.A. LeiteC.Q.F. PavanF.R. Sesti-CostaR. HeinrichT.A. Costa-NetoC.M. 6-Mercaptopurine complexes with silver and gold ions: Anti-tuberculosis and anti-cancer activities.Biomed. Pharmacother.201165533433810.1016/j.biopha.2011.04.012 21775091
    [Google Scholar]
  40. MaioreL. CinelluM.A. NobiliS. LandiniI. MiniE. GabbianiC. MessoriL. Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties.J. Inorg. Biochem.201210812312710.1016/j.jinorgbio.2011.11.007 22173093
    [Google Scholar]
  41. AliK.A. Abd-ElzaherM.M. MahmoudK. Synthesis and anticancer properties of silver(I) complexes containing 2,6-bis(substituted)pyridine derivatives.Int. J. Med. Chem.201320131710.1155/2013/256836 25386361
    [Google Scholar]
  42. LiS.X. ChenY.F. LuY. XuS.H. LiaoB.L. Synthesis, fluorescence, and anticancer activity of silver (I) complex based on 2-hydroxyquinoxaline ligand. Inorg. Nano-Met.Chem202050431532010.1080/24701556.2020.1711772
    [Google Scholar]
  43. AulakhJ.K. LobanaT.S. SoodH. AroraD.S. KaurR. SinghJ. Garcia-SantosI. KaurM. JasinskiJ.P. Silver derivatives of multi-donor heterocyclic thioamides as antimicrobial/anticancer agents: Unusual bio-activity against methicillin resistant S. aureus, S. epidermidis, and E. faecalis and human bone cancer MG63 cell line.RSC Advances2019927154701548710.1039/C9RA01804B 35514853
    [Google Scholar]
  44. StryjskaK. RadkoL. ChęcińskaL. KuszJ. PosyniakA. OchockiJ. Synthesis, spectroscopy, light stability, single-crystal analysis, and in vitro cytotoxic activity on HepG2 liver cancer of two novel silver(I) complexes of miconazole.Int. J. Mol. Sci.20202110362910.3390/ijms21103629
    [Google Scholar]
  45. LiW. ZhengM. ShangY. Synthesis, characterization, thermal behavior, and antitumor activities of an Ag (I) complex based on 4-(2-hydroxyphenyl)-2-methylpyrimidine.J. Chem. Res.20224631747519822110354110.1177/17475198221103541
    [Google Scholar]
  46. AlshamraniM. Recent advances and therapeutic journey of pyridine-based Cu(II) complexes as potent anticancer agents: A review (2015–2022).J. Coord. Chem.202376111910.1080/00958972.2022.2164190
    [Google Scholar]
  47. DamJ. IsmailZ. KurebwaT. GangatN. HarmseL. MarquesH.M. LemmererA. BodeM.L. de KoningC.B. Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo[1,2-a]pyridine complexes and their potential anticancer activity.Eur. J. Med. Chem.201712635336810.1016/j.ejmech.2016.10.041 27907874
    [Google Scholar]
  48. GeylK.K. BaykovS.V. KalininS.A. BunevA.S. TroshinaM.A. SharonovaT.V. SkripkinM.Y. KasatkinaS.O. PresnukhinaS.I. ShetnevA.A. KrasavinM.Y. BoyarskiyV.P. Synthesis, structure, and antiproliferative action of 2-pyridyl urea-based Cu(II) complexes.Biomedicines202210246110.3390/biomedicines10020461 35203671
    [Google Scholar]
  49. AnjomshoaM. HadadzadehH. Torkzadeh-MahaniM. FatemiS.J. Adeli-SardouM. RudbariH.A. NardoV.M. A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines.Eur. J. Med. Chem.201596668210.1016/j.ejmech.2015.04.020 25874332
    [Google Scholar]
  50. YuanB. HuJ. GuoY. ZhangJ. ZhangS. ZhangK. ZhaoJ. HouH. Nuclei DNA and mitochondria dual damages induced by thiosemicarbazone tripyridyl copper complexes with potential anti-tumor activity.Polyhedron202120311522510.1016/j.poly.2021.115225
    [Google Scholar]
  51. PathawL. KhamrangT. SelvakumaranB. MuraliM. Arul PrakashP. M JaabirM.S. VelusamyM. Synthesis, structure, characterization and biological evaluation of 3‐substituted 1‐pyridin‐2‐ylimidazo[1,5‐a]pyridine‐based copper(I)–phosphine complexes for anticancer drug screening.Appl. Organomet. Chem.2021351e602510.1002/aoc.6025
    [Google Scholar]
  52. MarzanoC. PelleiM. ColavitoD. AlidoriS. LobbiaG.G. GandinV. TisatoF. SantiniC. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.J. Med. Chem.200649257317732410.1021/jm0601248 17149861
    [Google Scholar]
  53. ShaikhS.A. BhatS.S. HegdeP.L. RevankarV.K. KateA. KirtaniD. KumbharA.A. KumbarV. BhatK. Synthesis, structural characterization, protein binding, DNA cleavage and anticancer activity of fluorophore labelled copper(ii) complexes based on 1,8-naphthalimide conjugates.New J. Chem.20214535163191633210.1039/D1NJ02696H
    [Google Scholar]
  54. ProsserK.E. ChangS.W. SaraciF. LeP.H. WalsbyC.J. Anticancer copper pyridine benzimidazole complexes: ROS generation, biomolecule interactions, and cytotoxicity.J. Inorg. Biochem.2017167899910.1016/j.jinorgbio.2016.11.006 27915178
    [Google Scholar]
  55. HouL. JiaX. WuY. LiJ. YaoD. GouY. HuangG. Aroylhydrazone Cu(II) complexes: Syntheses, crystal structures, and anticancer properties.J. Mol. Struct.2021123913046910.1016/j.molstruc.2021.130469
    [Google Scholar]
  56. RodićM.V. LeovacV.M. JovanovićL.S. SpasojevićV. JoksovićM.D. StanojkovićT. MatićI.Z. Vojinović-JešićL.S. MarkovićV. Synthesis, characterization, cytotoxicity and antiangiogenic activity of copper(II) complexes with 1-adamantoyl hydrazone bearing pyridine rings.Eur. J. Med. Chem.2016115758110.1016/j.ejmech.2016.03.003 27084495
    [Google Scholar]
  57. PanR.K. SongJ.L. LiG.B. LinS.Q. LiuS.G. YangG.Z. Copper(II), cobalt(II) and zinc(II) complexes based on a tridentate bis(benzimidazole)pyridine ligand: Synthesis, crystal structures, electrochemical properties and antitumour activities.Transit. Met. Chem.20174225326210.1007/s11243‑017‑0129‑9
    [Google Scholar]
  58. ChorobaK. MachuraB. Szlapa-KulaA. MaleckiJ.G. RaposoL. Roma-RodriguesC. CordeiroS. BaptistaP.V. FernandesA.R. Square planar Au(III), Pt(II) and Cu(II) complexes with quinoline-substituted 2,2′:6′,2″-terpyridine ligands: From in vitro to in vivo biological properties.Eur. J. Med. Chem.202121811340410.1016/j.ejmech.2021.113404 33823390
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206331002241119145651
Loading
/content/journals/acamc/10.2174/0118715206331002241119145651
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test